Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Non-cash Items: 2023-2025

Historic Non-cash Items for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$4.0 million.

  • BioLineRx's Non-cash Items rose 84.32% to -$4.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.0 million, marking a year-over-year increase of 84.32%. This contributed to the annual value of -$34.7 million for FY2024, which is 191.18% down from last year.
  • As of Q2 2025, BioLineRx's Non-cash Items stood at -$4.0 million, which was up 48.76% from -$7.7 million recorded in Q1 2025.
  • BioLineRx's Non-cash Items' 5-year high stood at $19.1 million during Q3 2023, with a 5-year trough of -$34.7 million in Q4 2024.
  • For the 3-year period, BioLineRx's Non-cash Items averaged around -$8.7 million, with its median value being -$7.7 million (2025).
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 423.52% in 2024, then spiked by 84.32% in 2025.
  • BioLineRx's Non-cash Items (Quarterly) stood at $19.1 million in 2023, then tumbled by 252.78% to -$34.7 million in 2024, then skyrocketed by 84.32% to -$4.0 million in 2025.
  • Its Non-cash Items was -$4.0 million in Q2 2025, compared to -$7.7 million in Q1 2025 and -$34.7 million in Q4 2024.